Navigation Links
Nile Therapeutics Reports 2010 Third Quarter Financial Results
Date:11/12/2010

significant blood pressure reduction at 5 ng/kg/min.  

Secondary and exploratory analyses at doses of 1.25 and 2.5 ng/kg/min demonstrated favorable effects of CD-NP on renal function, as compared to placebo. At these doses, CD-NP appeared to have favorable trends in biomarkers that are correlated with kidney function, including creatinine and cystatin-c. Data will be presented at an upcoming cardiology conference.

About Heart FailureHeart failure is the fastest-growing clinical cardiac disease in the U.S. according to the American Heart Association, affecting over 5 million Americans. Over 1 million patients in the U.S. each year are hospitalized with ADHF, an acute exacerbation of heart failure. This hospitalization rate is almost double the rate seen 15 years ago, and is the most frequent cause of hospital admission in the U.S. for patients older than 65 years, generating annual inpatient costs of more than $33 billion.

About Nile TherapeuticsNile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical needs. Nile is initially focusing its efforts on developing its lead compound, CD-NP, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure, and CU-NP, a novel rationally designed natriuretic peptide. More information on Nile can be found at http://www.nilethera.com.

Safe Harbor Paragraph for Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding the timing, progress and anticipated results of the clinical development, regulatory processes, clinical trial timeli
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... , Sept. 15, 2014 /PRNewswire-iReach/ -- Asthma ... persons of all ages, but most commonly starts ... characterized by narrowing of the airways, leading to ... lungs come into contact with endogenous and exogenous ... events, such as swelling of the airways, tightening ...
(Date:9/15/2014)... MedicOne Medical Response, a leading provider emergency and ... Inc. Magazine as one of the fastest growing ... - http://photos.prnewswire.com/prnh/20140914/145997 The ... with the largest revenue growth between 2010 and ... ambulance companies to make the list, achieved an ...
(Date:9/15/2014)... -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI ... 2014, regular quarterly dividend payment of $0.15 per share ... September 5, 2014, the record date. About ... of patents and royalty assets, consisting primarily of its ... with various biotechnology and pharmaceutical companies. PDL pioneered the  ...
Breaking Medicine Technology:Asthma Market to Reach 161.02 million Cases in 10MM by 2023 2Asthma Market to Reach 161.02 million Cases in 10MM by 2023 3Asthma Market to Reach 161.02 million Cases in 10MM by 2023 4Asthma Market to Reach 161.02 million Cases in 10MM by 2023 5MedicOne Medical Response Named to 2014 Inc. 5000 Fastest Growing Companies List 2MedicOne Medical Response Named to 2014 Inc. 5000 Fastest Growing Companies List 3PDL BioPharma Completes Regular Quarterly Dividend Payment 2
... 11, 2011 Vanda Pharmaceuticals Inc. (NASDAQ: ... Corporation, an affiliate of Vanda,s sublicensor Novartis Pharma ... the long-acting injectable (or depot) formulation of Fanapt® ... will evaluate the safety and pharmacokinetic profiles of ...
... 11, 2011 Merck (NYSE: MRK ), ... and Intercell AG (VSE: ICLL) today announced that following ... trial evaluating V710, an investigational vaccine for the prevention ... Monitoring Committee (DMC) recommended suspension of enrollment. Although the ...
Cached Medicine Technology:Vanda Pharmaceuticals Announces Commencement of Clinical Study of Long-Acting Injectable Formulation of Fanapt® 2Vanda Pharmaceuticals Announces Commencement of Clinical Study of Long-Acting Injectable Formulation of Fanapt® 3Update on Phase II/III Clinical Trial of Investigational Staphylococcus aureus Vaccine, V710 2Update on Phase II/III Clinical Trial of Investigational Staphylococcus aureus Vaccine, V710 3
(Date:9/15/2014)... Today, Zane Benefits, the #1 Online Health Benefits ... radio show. , According to Zane Benefits, health ... doesn’t make sense to choose a “one size fits ... and employee as much as 60 percent on health ... Speaking on Business , Chris Redgrave, highlights the rising ...
(Date:9/15/2014)... UC San Francisco researchers have used brain scans to ... a possible tool to spot children with dyslexia and ... , In the United States, children usually learn to ... proficient readers by third grade, according to the authors. ... kindergarteners as they were learning to read formally at ...
(Date:9/15/2014)... from the prospective Prostate, Lung, Colorectal and Ovarian (PLCO) ... baldness affecting both the front and the crown of ... increased risk of developing aggressive prostate cancer (usually indicates ... to non-aggressive prostate cancer) later in life, compared to ... between other patterns of baldness and prostate cancer risk. ...
(Date:9/15/2014)... 2014 In order to provide predictability ... act conjointly to quantify, define and model medical practice. ... integral part of medical care. , The Journal of ... conducted by the non-profit Institute of BioAcoustic Biology, located ... math can be much more than a measurement tool; ...
(Date:9/15/2014)... Amy Norton HealthDay ... A relatively small number of medications are responsible for sending ... a U.S. government study finds. Each year between 2007 ... were hospitalized after getting a hold of family members, medication, ... "Three-quarters of those children were just 1 or ...
Breaking Medicine News(10 mins):Health News:Zane Benefits Featured on Zions Bank Speaking on Business 2Health News:Study first to use brain scans to forecast early reading difficulties 2Health News:Certain form of baldness at age 45 linked to higher risk of aggressive prostate cancer 2Health News:Math as Medicine: The Promise of Frequency Domain BioMarkers as a Template to Predict, Enchance and Promote Optimal Health 2Health News:Math as Medicine: The Promise of Frequency Domain BioMarkers as a Template to Predict, Enchance and Promote Optimal Health 3Health News:Small Number of Drugs Behind Kids' Accidental Poisonings: CDC 2Health News:Small Number of Drugs Behind Kids' Accidental Poisonings: CDC 3
... Bulletin Board: GXYF), a leading developer and marketer of,cheese ... today announced that it will host an investor conference ... the 2008 fiscal year at,11:00 a.m. EST on Friday, ... results before the market opens the same day., ...
... ROCHESTER, Minn. -- Liver transplant is a life saving ... the need for donor livers far exceeds the supply. ... a donor liver will receive one, and some patients ... Clinic Proceedings, physicians explore how the current system for ...
... for,employers throughout the world are expected to accelerate ... of insurance companies conducted by Watson,Wyatt Worldwide, a ... in a vast majority of countries, medical cost ... Nearly three-fourths (71 percent) of respondents expect higher ...
... Co-Founder Todd Rosengart Offers Lifesaving Tips in the Fight ... ... data released from,the Center for Disease Control indicates that deaths resulting ... such as obesity, high blood pressure and high cholesterol remain on,the ...
... also available in German . , In ... childless against their will. The microscopic procedure significantly improves the ... discovered by scientists at the University of Bonn together with ... 124 women. Up to now, the desire to have a ...
... Reston, Va.Researchers involved in a large, multi-institutional study comparing ... tomography (CT) in the characterization of lung nodules found ... or not a nodule was malignant. , CT and ... nodules (SPNs) as benign or malignant, said James W. ...
Cached Medicine News:Health News:Galaxy Nutritional Foods Announces Third Quarter FY2008 Earnings Conference Call for Friday, February 8, 2008 2Health News: Mayo Clinic Proceedings contributors discuss impact of donor organ allocation system 2Health News: Mayo Clinic Proceedings contributors discuss impact of donor organ allocation system 3Health News:Medical Cost Increases to Accelerate Worldwide Over Next Five Years, Watson Wyatt Poll Finds 2Health News:Medical Cost Increases to Accelerate Worldwide Over Next Five Years, Watson Wyatt Poll Finds 3Health News:Vitals.com 'Goes Red' for American Heart Month 2Health News:Vitals.com 'Goes Red' for American Heart Month 3Health News:Significantly higher success rates with artificial insemination 2Health News:PET outperforms CT in characterization of lung nodules 2
...
...
... exercise BP monitor is designed to automatically ... diastolic BP along with heart rate. It's ... use in treadmill, ergometer and pharmacological stress ... use in research environments., ,Tango excels ...
...
Medicine Products: